SCHEMBL4472632

SCHEMBL4472632

Oc1ccccc1Oc1ccnc2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.43
NCF1 P14598 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.41
MAPT P10636 4/20 0.40
LMNA P02545 3/20 0.40
GAA P10253 2/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HTT P42858 2/20 0.40
KMT2A Q03164 2/20 0.40
MCL1 Q07820 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
JAK2 O60674 1/20 0.40
HPGD P15428 1/20 0.40
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
BRAF P15056 1/20 0.39
KDR P35968 1/20 0.39
MAPK14 Q16539 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9431770 0.87 NCF1 (0.54) KDM4ENCF1LOXL2MAPTALDH1A1
SCHEMBL7461560 0.82 LMNA (0.51) MAPTLMNAGAAMEN1ALDH1A1
SCHEMBL27665935 0.79 PDGFRB (0.49) MAPTLMNAGAAMEN1ALDH1A1
SCHEMBL1591720 0.79 NCF1 (0.56) KDM4ENCF1LOXL2MAPTLMNA
SCHEMBL4766092 0.79 RAB9A (0.46) NCF1LOXL2MEN1KMT2ABRAF
SCHEMBL7482565 0.78 SRC (0.53) KDM4EMAPTGAAMEN1ALDH1A1
SCHEMBL1897179 0.77 ERBB2 (0.55) KDM4ENCF1LOXL2MAPTLMNA
SCHEMBL1591789 0.76 CA2 (0.47) NCF1LOXL2MAPTBRAFKDR
SCHEMBL5826025 0.76 SETDB1 (0.43) NCF1LOXL2MAPTLMNAHPGD
SCHEMBL23069169 0.76 NCF1 (0.43) KDM4ENCF1LOXL2MAPTBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7135466-B2 Quinoline and quinazoline derivatives and drugs containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-11-14 US disclosed
US-20060211717-A1 Quinoline and quinazoline derivatives and drugs containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-21 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed
US-20040132727-A1 Quinoline and quinazoline derivatives and drugs containing the same KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2004-07-08 US disclosed
EP-1243582-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2002-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211717-A1 Quinoline and quinazoline derivatives and drugs containing the same PDGFRA, PDGFRB, PDGFA KDM4E 1657/4885NCF1 3890/4885LOXL2 1569/4885
US-20040132727-A1 Quinoline and quinazoline derivatives and drugs containing the same PDGFRA, PDGFRB, PDGFA KDM4E 1526/4885NCF1 3664/4885LOXL2 1690/4885
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 KDM4E 1982/4885NCF1 960/4885LOXL2 4099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.